CDER’s 2005 Performance By The Numbers
The Center for Drug Evaluation & Research issued its annual fiscal year 1Report To The Nation: Improving Public Health Through Human Drugs Aug. 18, outlining its performance in fiscal year 2005. The following data are some performance statistics provided by the agency. In his Director's message, Steven Galson touted CDER as being "more transparent, flexible, results-oriented and high-performing."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth